Creditos
Bus.Valor
Conectar
Bus.User
Desde:
23/10/2020
OFF:
12 Min
Mensaje de: ECS1 Hora: 07/05/2025 10:10:39
Dice jazz . Zepzelca remains the leading treatment in second-line small cell lung cancer based ..........
Dice jazz . Zepzelca remains the leading treatment in second-line small cell lung cancer based ..........
javi, tarla subió sus ventas un 20% en el 1T. Imaginando que tuviera un 15% del mercado. Eso significa que ha subido a 18%, es decir, nos ha quitado un 3%.
La caida sobre las ventas que se esperaban son seguramente 7% por haber una semana de ventas menos, 3% por perdida de mercado reapecto a tarla y el resto por el cambio de protocolo en SCLC-LS. Excepto lo de tarla lo demás debería ir compensandolo estos meses que viene.
Digo yo.
La caida sobre las ventas que se esperaban son seguramente 7% por haber una semana de ventas menos, 3% por perdida de mercado reapecto a tarla y el resto por el cambio de protocolo en SCLC-LS. Excepto lo de tarla lo demás debería ir compensandolo estos meses que viene.
Digo yo.
4
Mensaje de: Aplidino Hora: 07/05/2025 7:59:01
No te preocupes, entramos en cónclave...
No te preocupes, entramos en cónclave...
En conclave llevamos desde octubre, creo recordar, la pregunta es si el 22 de mayo o el 4 de junio tendremos fumata blanca.
(1)
2
Mensaje de: ysisí Hora: 07/05/2025 4:52:22
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
Si, el tarla nos está comiendo mercado en 2L y seguirá haciendolo. Por otra parte, parte de los que eligen Tarla luego ya en 3L tienen Lurbi. Pero es mucho menos tiempo.
Ya es hora de irnos a 1L. A ver si a partir del verano.
Ya es hora de irnos a 1L. A ver si a partir del verano.
10
Mensaje de: ysisí Hora: 07/05/2025 4:52:22
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
Pues ya sabemos que un 7% menos es por haber tenido una semana menos, ahora hace falta saber que parte es por el desplazamiento del 50% de los pacientes de segunda linea que vienen de LS y se trataran unos meses despues y el resto es tarla.
(2)
10
Mensaje de: ysisí Hora: 07/05/2025 4:52:22
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
Again, Jess, I think you covered it very well, Renee. With our new data and ultimately adoption into NCCN and and in the label as first line, you know, that that affords us a larger population for a longer duration of therapy. Tirilatumab is not approved in that in that setting, and it would be quite a while before a new trial would read out there.
10
Mensaje de: ysisí Hora: 07/05/2025 4:52:22
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
And so this is something we look forward to presenting at ASCO and then rapidly submitting that data for potential inclusion in NCCN treatment guidelines. We do expect this data to be practice changing, and therefore, going into the first line, we look to a larger patient population to treat in the extensive stage, patients, but also longer treatment duration. So we do expect this to contribute to future growth of the brand, and we would also expect, patients that didnt receive Zepzelca in first line to have the opportunity to receive it in the second line.
10
Mensaje de: ysisí Hora: 07/05/2025 4:52:22
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
I am happy to jump in and take that one. So as we think about Zepzelca, we did have some dynamics impacting the first quarter. As we look forward though to your point on Zepzelca returning to growth, even with competition and some, delayed progression of first line limited stage patients coming into the second line, Zepzelca in the second line still remains the leading treatment as measured by market share. Importantly, we do look forward to both sharing our data at ASCO on the first line and FORTE trial where we showed stat say, again, clinically meaningful PFS and OS in our study of first line extensive stage maintenance patients.
10
Mensaje de: ysisí Hora: 07/05/2025 4:52:22
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We also believe Zepzelcas potential expansion into first line maintenance therapy will provide more patients the ability to receive treatment for a longer duration.
10
Mensaje de: ysisí Hora: 07/05/2025 4:52:22
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
We submitted a supplemental new drug application or sNDA to expand Zepzelca into first line maintena..........
For 2025, we anticipate no direct financial impact from these tariffs
10
Mostrar mas Mensajes
